ResearcherIcahn School of Medicine at Mount SinaiActive in the last 2 years
Keith Magnus Sigel
Matched on ORCID iD 0000-0002-4051-4861; OpenAlex author ID A5049808872. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 5
- Impact of β-Blockers, Statins, and Cholinergic Agents on Clinical Outcomes in Pancreatic Cancer: A Retrospective VA Cohort Study. Co-author DOI 10.1158/1055-9965.epi-26-0062↗
- Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving chemotherapy. Co-author DOI 10.1093/jncics/pkaf024↗
- Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2023.4254↗
- Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
- Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Co-author DOI 10.1053/j.seminoncol.2021.02.001↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susan Elaine Bates · 3 shared papers, 2021–2026 · strength 0.59
- Paper Impact of β-Blockers, Statins, and Cholinergic Agents on Clinical Outcomes in Pancreatic Cancer: A Retrospective VA Coh… DOI 10.1158/1055-9965.epi-26-0062↗
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Tito Fojo · 3 shared papers, 2021–2026 · strength 0.59
- Paper Impact of β-Blockers, Statins, and Cholinergic Agents on Clinical Outcomes in Pancreatic Cancer: A Retrospective VA Coh… DOI 10.1158/1055-9965.epi-26-0062↗
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Deirdre Jill Cohen · 2 shared papers, 2023–2025 · strength 0.47
- Paper Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving che… DOI 10.1093/jncics/pkaf024↗
- Paper Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receivi… DOI 10.1001/jamanetworkopen.2023.4254↗
- Arielle J. Labiner · 2 shared papers, 2023–2025 · strength 0.47
- Paper Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving che… DOI 10.1093/jncics/pkaf024↗
- Paper Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receivi… DOI 10.1001/jamanetworkopen.2023.4254↗
- Daniel Jeremy Fulop · 2 shared papers, 2023–2025 · strength 0.47
- Paper Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving che… DOI 10.1093/jncics/pkaf024↗
- Paper Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receivi… DOI 10.1001/jamanetworkopen.2023.4254↗
- Aimee Lee Lucas · 2 shared papers, 2023–2025 · strength 0.47
- Paper Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving che… DOI 10.1093/jncics/pkaf024↗
- Paper Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receivi… DOI 10.1001/jamanetworkopen.2023.4254↗
- Ruth Aroon White · 1 shared paper, 2026 · strength 0.33
- Jason Cham · 1 shared paper, 2026 · strength 0.33
- Jiheum Park · 1 shared paper, 2026 · strength 0.33
- Emma W. Gong · 1 shared paper, 2025 · strength 0.28
- Thierry Conroy · 2 shared papers, 2021–2023 · strength 0.26
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Celine Yeh · 2 shared papers, 2021–2023 · strength 0.26
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Haley M. Zylberberg · 1 shared paper, 2023 · strength 0.18
- Yvonne M. Saenger · 1 shared paper, 2023 · strength 0.15
- Marc Ychou · 1 shared paper, 2023 · strength 0.15
- Gayle Jameson · 1 shared paper, 2023 · strength 0.15
- Rachael Ann Safyan · 1 shared paper, 2023 · strength 0.15
- Elizabeth M. Hecht · 1 shared paper, 2023 · strength 0.15
- John A. Chabot · 1 shared paper, 2023 · strength 0.15
- Gulam Abbas Manji · 1 shared paper, 2023 · strength 0.15
- Daniel D. Von Hoff · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.